Latest News
SAB Biotherapeutics, Inc.
- SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
- Nasdaq issues removal notice for SAB Biotherapeutics (NASDAQ: SABS) warrant expiring October 22, 2026.
- Is SAB Biotherapeutics (NASDAQ:SABS) In A Good Position To Invest In Growth?
- SAB Biotherapeutics to present at Chardan Healt...
- SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
- A New York healthcare conference will feature SAB BIO's CEO in a fireside chat
- SAB Biotherapeutics Warrant (SABSW) Flat at $0.01 as Sub-Penny Quoting Persists - Wave Extension
- SAB Biotherapeutics Wins FDA Fast Track for SAB-142
- SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
- SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
- SAB Biotherapeutics Warrant (SABSW) Trades Flat at $0.01 as Directional Signals Remain Elusive - Protective Put
Headlines from the last 30 days, linking to the original publishers. See all market news →